Ha Jeonghoon, Jo Kwanhoon, Kang Borami, Kim Min Hee, Lim Dong Jun
Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Endocrinol Metab (Seoul). 2016 Sep;31(3):476-479. doi: 10.3803/EnM.2016.31.3.476. Epub 2016 Jul 26.
Cholestyramine (CS) is an ion exchange resin, which binds to iodothyronines and would lower serum thyroid hormone level. The use of CS added to conventional antithyroid drugs to control thyrotoxicosis has been applied since 1980's, and several studies indicate that using CS in combination with methimazole (MZ) produces a more rapid decline in serum thyroid hormones than with only MZ treatment. Our recent retrospective review of five patients taking high dose MZ and CS, compared to age-, gender-, initial free thyroxine (T4) level-, and MZ dose-matched 12 patients with MZ use only, showed more rapid decline of both free T4 and triiodothyronine levels without more adverse events. CS could be safely applicable short-term adjunctive therapy when first-line antithyroid medications are not enough to adequately control severe thyrotoxicosis or side effects of antithyroid drug would be of great concern.
消胆胺(CS)是一种离子交换树脂,它能与碘甲状腺原氨酸结合,从而降低血清甲状腺激素水平。自20世纪80年代以来,消胆胺就被用于添加到传统抗甲状腺药物中以控制甲状腺毒症,多项研究表明,与单独使用甲巯咪唑(MZ)相比,消胆胺与甲巯咪唑联合使用能使血清甲状腺激素下降得更快。我们最近对5名服用高剂量甲巯咪唑和消胆胺的患者进行了回顾性研究,与年龄、性别、初始游离甲状腺素(T4)水平和甲巯咪唑剂量相匹配的12名仅使用甲巯咪唑的患者相比,结果显示游离T4和三碘甲状腺原氨酸水平下降得更快,且没有更多不良事件。当一线抗甲状腺药物不足以充分控制严重甲状腺毒症或对抗甲状腺药物的副作用极为担忧时,消胆胺可作为安全适用的短期辅助治疗药物。